中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (11): 1125-1131.doi: 10.3969/j.issn.1000-6621.2021.11.005
收稿日期:
2021-08-21
出版日期:
2021-11-10
发布日期:
2021-11-02
通信作者:
高谦
E-mail:qiangao@fudan.edu.cn
Received:
2021-08-21
Online:
2021-11-10
Published:
2021-11-02
Contact:
GAO Qian
E-mail:qiangao@fudan.edu.cn
摘要:
人体从感染结核分枝杆菌到发病是一个复杂的连续的过程,这一过程被人为地划分成多个阶段。以往的科学研究、诊断检测和药物治疗主要关注潜伏感染和活动性结核病,而结核病的持续高疫情使人们逐渐关注其他的阶段。结核病自然史不同阶段的定义及对每个阶段特征的理解对研发新的诊断技术和制定更合理的干预措施至关重要。笔者就结核分枝杆菌自然史的各个阶段的定义及其特征,以及各阶段诊断的现状与发展方向进行综述,希望能够为研发结核病诊断技术和制定预防干预措施提供思考。
李蒙, 高谦. 结核病自然史的阶段划分及其诊断的现状与展望[J]. 中国防痨杂志, 2021, 43(11): 1125-1131. doi: 10.3969/j.issn.1000-6621.2021.11.005
LI Meng, GAO Qian. Stages in the natural history of tuberculosis and the current status and prospect of diagnosis[J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1125-1131. doi: 10.3969/j.issn.1000-6621.2021.11.005
[1] | World Health Organization. The end TB strategy. Geneva: World Health Organization, 2014. |
[2] |
Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med, 2020, 382(22):2081-2090. doi: 10.1056/NEJMoa2008457.
doi: 10.1056/NEJMoa2008457 |
[3] |
Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles’ Heel of current strategies to control Covid-19. N Engl J Med, 2020, 382(22):2158-2160. doi: 10.1056/NEJMe2009758.
doi: 10.1056/NEJMe2009758 |
[4] |
Kendall EA, Shrestha S, Dowdy DW. The epidemiological importance of subclinical tuberculosis: a critical re-appraisal. Am J Respir Crit Care Med, 2020, 203(2):168-174. doi: 10.1164/rccm.202006-2394PP.
doi: 10.1164/rccm.202006-2394PP |
[5] |
Drain PK, Bajema KL, Dowdy D, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev, 2018, 31(4):e00021-18. doi: 10.1128/CMR.00021-18.
doi: 10.1128/CMR.00021-18 |
[6] |
Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis, 2011, 204 Suppl 4(Suppl 4): S1179-86. doi: 10.1093/infdis/jir451.
doi: 10.1093/infdis/jir451 |
[7] |
Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol, 2009, 17(5):183-188. doi: 10.1016/j.tim.2009.02.005.
doi: 10.1016/j.tim.2009.02.005 |
[8] | World Health Organization. Development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Geneva: World Health Organization, 2017. |
[9] |
Li H, Wang XX, Wang B, et al. Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis. Proc Natl Acad Sci U S A, 2017, 114(19):5023-5028. doi: 10.1073/pnas.1611776114.
doi: 10.1073/pnas.1611776114 |
[10] | World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2014. |
[11] |
Getahun H, Matteelli A, Chaisson RE, et al. Latent Mycobacterium tuberculosis infection. N Engl J Med, 2015, 372(22):2127-2135. doi: 10.1056/NEJMra1405427.
doi: 10.1056/NEJMra1405427 |
[12] |
Lin PL, Ford CB, Coleman MT, et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med, 2014, 20(1):75-79. doi: 10.1038/nm.3412.
doi: 10.1038/nm.3412 |
[13] |
Liu Q, Wei J, Li Y, et al. Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments. Sci Adv, 2020, 6(22): eaba4901. doi: 10.1126/sciadv.aba4901.
doi: 10.1126/sciadv.aba4901 |
[14] |
Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M.tuberculosis? A TBNET consensus statement. Eur Respir J, 2009, 33(5):956-973. doi: 10.1183/09031936.00120908.
doi: 10.1183/09031936.00120908 |
[15] |
Blumberg HM, Ernst JD. The challenge of latent TB infection. JAMA, 2016, 316(9):931-933. doi: 10.1001/jama.2016.11021.
doi: 10.1001/jama.2016.11021 |
[16] |
Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ, 2018, 362:k2738. doi: 10.1136/bmj.k2738.
doi: 10.1136/bmj.k2738 |
[17] |
Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep, 2020, 69(1):1-11. doi: 10.15585/mmwr.rr6901a1.
doi: 10.15585/mmwr.rr6901a1 |
[18] |
Stiehm RH. Subclinical pulmonary tuberculosis; a presentation of forty cases. Ann Intern Med, 1940, 13(12):2285-2305. doi: 10.7326/0003-4819-13-12-2285.
doi: 10.7326/0003-4819-13-12-2285 |
[19] |
Xu Y, Cancino-Muñoz I, Torres-Puente M, et al. High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain. PLoS Med, 2019, 16(10):e1002961. doi: 10.1371/journal.pmed.1002961.
doi: 10.1371/journal.pmed.1002961 |
[20] |
Kendall EA, Kitonsa PJ, Nalutaaya A, et al. The spectrum of tuberculosis disease in an urban ugandan community and its health facilities. Clin Infect Dis, 2021, 72(12):e1035-e1043. doi: 10.1093/cid/ciaa1824.
doi: 10.1093/cid/ciaa1824 |
[21] | 全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012, 34(8):485-508. |
[22] |
Loudon RG, Roberts RM. Droplet expulsion from the respiratory tract. Am Rev Respir Dis, 1967, 95(3):435-442. doi: 10.1164/arrd.1967.95.3.435.
doi: 10.1164/arrd.1967.95.3.435 |
[23] |
van’t Hoog AH, Laserson KF, Githui WA, et al. High preva-lence of pulmonary tuberculosis and inadequate case finding in rural western Kenya. Am J Respir Crit Care Med, 2011, 183(9):1245-1253. doi: 10.1164/rccm.201008-1269OC.
doi: 10.1164/rccm.201008-1269OC |
[24] |
Onozaki I, Law I, Sismanidis C, et al. National tuberculosis prevalence surveys in Asia, 1990—2012: an overview of results and lessons learned. Trop Med Int Health, 2015, 20(9):1128-1145. doi: 10.1111/tmi.12534.
doi: 10.1111/tmi.12534 |
[25] |
Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet, 1999, 353(9151):444-449. doi: 10.1016/s0140-6736(98)03406-0.
doi: 10.1016/s0140-6736(98)03406-0 |
[26] |
Tostmann A, Kik SV, Kalisvaart NA, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis, 2008, 47(9):1135-1142. doi: 10.1086/591974.
doi: 10.1086/591974 |
[27] |
Hernández-Garduño E, Cook V, Kunimoto D, et al. Transmission of tuberculosis from smear negative patients: a mole-cular epidemiology study. Thorax, 2004, 59(4):286-290. doi: 10.1136/thx.2003.011759.
doi: 10.1136/thx.2003.011759 |
[28] |
Lohmann EM, Koster BF, le Cessie S, et al. Grading of a positive sputum smear and the risk of Mycobacterium tuberculosis transmission. Int J Tuberc Lung Dis, 2012, 16(11):1477-1484. doi: 10.5588/ijtld.12.0129.
doi: 10.5588/ijtld.12.0129 |
[29] |
Yang C, Shen X, Peng Y, et al. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clin Infect Dis, 2015, 61(2):219-227. doi: 10.1093/cid/civ255.
doi: 10.1093/cid/civ255 |
[30] |
Patterson B, Wood R. Is cough really necessary for TB transmission? Tuberculosis (Edinb), 2019, 117:31-35. doi: 10.1016/j.tube.2019.05.003.
doi: 10.1016/j.tube.2019.05.003 |
[31] |
Loudon RG, Roberts RM. Singing and the dissemination of tuberculosis. Am Rev Respir Dis, 1968, 98(2):297-300. doi: 10.1164/arrd.1968.98.2.297.
doi: 10.1164/arrd.1968.98.2.297 |
[32] |
Esmail H, Dodd PJ, Houben RMGJ. Tuberculosis transmission during the subclinical period: could unrelated cough play a part? Lancet Respir Med, 2018, 6(4):244-246. doi: 10.1016/S2213-2600(18)30105-X.
doi: 10.1016/S2213-2600(18)30105-X |
[33] |
Houben RMGJ, Esmail H, Emery JC, et al. Spotting the old foe-revisiting the case definition for TB. Lancet Respir Med, 2019, 7(3):199-201. doi: 10.1016/S2213-2600(19)30038-4.
doi: 10.1016/S2213-2600(19)30038-4 |
[34] |
Tiemersma EW, van der Werf MJ, Borgdorff MW, et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One, 2011, 6(4):e17601. doi: 10.1371/journal.pone.0017601.
doi: 10.1371/journal.pone.0017601 |
[35] |
中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi: 10.3969/i.issn.1000-6621.2020.08.001.
doi: 10.3969/i.issn.1000-6621.2020.08.001 |
[36] |
O’Garra A, Redford PS, McNab FW, et al. The immune response in tuberculosis. Annu Rev Immunol, 2013, 31:475-527. doi: 10.1146/annurev-immunol-032712-095939.
doi: 10.1146/annurev-immunol-032712-095939 |
[37] |
Liao CH, Lai CC, Tan CK, et al. False-negative results by enzyme-linked immunospot assay for interferon-gamma among patients with culture-confirmed tuberculosis. J Infect, 2009, 59(6):421-423. doi: 10.1016/j.jinf.2009.09.012.
doi: 10.1016/j.jinf.2009.09.012 |
[38] |
Dorman SE, Belknap R, Graviss EA, et al. Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med, 2014, 189(1):77-87. doi: 10.1164/rccm.201302-0365OC.
doi: 10.1164/rccm.201302-0365OC |
[39] |
Zhou G, Luo Q, Luo S, et al. Interferon-gamma release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis, 2020, 20(12):1457-1469. doi: 10.1016/S1473-3099(20)30276-0.
doi: 10.1016/S1473-3099(20)30276-0 |
[40] |
Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, et al. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. Lancet Glob Health, 2021, 9(6):e841-e853. doi: 10.1016/S2214-109X(21)00045-0.
doi: 10.1016/S2214-109X(21)00045-0 |
[41] |
Blount RJ, Tran MC, Everett CK, et al. Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays. BMC Public Health, 2016, 16(1):875. doi: 10.1186/s12889-016-3519-6.
doi: 10.1186/s12889-016-3519-6 |
[42] |
Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, 2016, 387(10035):2312-2322. doi: 10.1016/S0140-6736(15)01316-1.
doi: 10.1016/S0140-6736(15)01316-1 |
[43] |
Scriba TJ, Penn-Nicholson A, Shankar S, et al. Sequential inflammatory processes define human progression from M.tuberculosis infection to tuberculosis disease. PLoS Pathog, 2017, 13(11):e1006687. doi: 10.1371/journal.ppat.1006687.
doi: 10.1371/journal.ppat.1006687 |
[44] |
Gupta RK, Turner CT, Venturini C, et al. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respir Med, 2020, 8(4):395-406. doi: 10.1016/S2213-2600(19)30282-6.
doi: 10.1016/S2213-2600(19)30282-6 |
[45] |
Weiner J 3rd, Maertzdorf J, Sutherland JS, et al. Metabolite changes in blood predict the onset of tuberculosis. Nat Commun, 2018, 9(1):5208. doi: 10.1038/s41467-018-07635-7.
doi: 10.1038/s41467-018-07635-7 |
[46] |
Gupta RK, Calderwood CJ, Yavlinsky A, et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med, 2020, 26(12):1941-1949. doi: 10.1038/s41591-020-1076-0.
doi: 10.1038/s41591-020-1076-0 |
[47] |
Mpande CAM, Rozot V, Mosito B, et al. Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection. EBioMedicine, 2021, 64:103233. doi: 10.1016/j.ebiom.2021.103233.
doi: 10.1016/j.ebiom.2021.103233 |
[48] |
Jiang Q, Ji L, Qiu Y, et al. A randomised controlled trial of stepwise sputum collection to increase yields of confirmed tuberculosis. Int J Tuberc Lung Dis, 2019, 23(6):685-691. doi: 10.5588/ijtld.18.0524.
doi: 10.5588/ijtld.18.0524 |
[49] |
Dodd PJ, Gardiner E, Coghlan R, et al. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health, 2014, 2(8):e453-9. doi: 10.1016/S2214-109X(14)70245-1.
doi: 10.1016/S2214-109X(14)70245-1 |
[50] | World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Geneva: World Health Organization, 2015. |
[51] |
Shah M, Hanrahan C, Wang ZY, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults. Cochrane Database Syst Rev, 2016, 2016(5): CD011420. doi: 10.1002/14651858.CD011420.pub2.
doi: 10.1002/14651858.CD011420.pub2 |
[52] |
Nkereuwem E, Togun T, Gomez MP, et al. Comparing accuracy of lipoarabinomannan urine tests for diagnosis of pulmonary tuberculosis in children from four African countries: a cross-sectional study. Lancet Infect Dis, 2021, 21(3):376-384. doi: 10.1016/S1473-3099(20)30598-3.
doi: 10.1016/S1473-3099(20)30598-3 |
[53] |
Warsinske HC, Rao AM, Moreira FMF, et al. Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response. JAMA Netw Open, 2018, 1(6):e183779. doi: 10.1001/jamanetworkopen.2018.3779.
doi: 10.1001/jamanetworkopen.2018.3779 |
[54] |
Ahmad R, Xie L, Pyle M, et al. A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough. Sci Transl Med, 2019, 11(515): eaaw8287. doi: 10.1126/scitranslmed.aaw8287.
doi: 10.1126/scitranslmed.aaw8287 |
[55] |
寿娟, 谢青梅, 龙昭玲, 等. 胸水游离DNA的结核杆菌检测在结核病诊断中的价值. 中华病理学杂志, 2018, 47(6):465-467. doi: 10.3760/cma.j.issn.0529-5807.2018.06.016.
doi: 10.3760/cma.j.issn.0529-5807.2018.06.016 |
[56] |
韩冰, 胡柳杨, 姚亚超, 等. 血浆结核分枝杆菌游离DNA检测对结核病的诊断价值. 临床肺科杂志, 2020, 25(6):883-887. doi: 10.3969/j.issn.1009-6663.2020.06.018.
doi: 10.3969/j.issn.1009-6663.2020.06.018 |
[57] |
韩冰, 胡柳杨, 曹东林. 游离DNA检测在结核病诊断中的研究进展. 检验医学与临床, 2020, 17(3):419-423. doi: 10.3969/j.issn.1672-9455.2020.03.042.
doi: 10.3969/j.issn.1672-9455.2020.03.042 |
[58] |
Oreskovic A, Panpradist N, Marangu D, et al. Diagnosing pulmonary tuberculosis by using sequence-specific purification of urine cell-free DNA. J Clin Microbiol, 2021, 59(8):e0007421. doi: 10.1128/JCM.00074-21.
doi: 10.1128/JCM.00074-21 |
[59] |
Beccaria M, Mellors TR, Petion JS, et al. Preliminary investigation of human exhaled breath for tuberculosis diagnosis by multidimensional gas chromatography-Time of flight mass spectrometry and machine learning. J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1074-1075:46-50. doi: 10.1016/j.jchromb.2018.01.004.
doi: 10.1016/j.jchromb.2018.01.004 |
[60] |
Beccaria M, Bobak C, Maitshotlo B, et al. Exhaled human breath analysis in active pulmonary tuberculosis diagnostics by comprehensive gas chromatography-mass spectrometry and chemometric techniques. J Breath Res, 2018, 13(1):016005. doi: 10.1088/1752-7163/aae80e.
doi: 10.1088/1752-7163/aae80e |
[61] |
Saktiawati AMI, Triyana K, Wahyuningtias SD, et al. eNose-TB: A trial study protocol of electronic nose for tuberculosis screening in Indonesia. PLoS One, 2021, 16(4):e0249689. doi: 10.1371/journal.pone.0249689.
doi: 10.1371/journal.pone.0249689 |
[62] |
Hoang LT, Jain P, Pillay TD, et al. Transcriptomic signatures for diagnosing tuberculosis in clinical practice: a prospective, multicentre cohort study. Lancet Infect Dis, 2021, 21(3):366-375. doi: 10.1016/S1473-3099(20)30928-2.
doi: 10.1016/S1473-3099(20)30928-2 |
[1] | 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 中国防痨协会《中国防痨杂志》编辑委员会. 耐药肺结核全口服化学治疗方案中国专家共识(2021年版)[J]. 中国防痨杂志, 2021, 43(9): 859-866. |
[2] | 首都医科大学附属北京胸科医院, 《中国防痨杂志》编辑委员会. 抗结核药治疗药物监测临床应用专家共识[J]. 中国防痨杂志, 2021, 43(9): 867-873. |
[3] | 中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识[J]. 中国防痨杂志, 2021, 43(9): 874-878. |
[4] | 周文强, 张爽, 初乃惠. 耐药肺结核全口服治疗方案研究的现状和展望[J]. 中国防痨杂志, 2021, 43(9): 879-882. |
[5] | 逄宇, 高兴辉, 汤一苇, 高孟秋. 基于结核病宿主免疫反应的实验室检测技术及其临床应用[J]. 中国防痨杂志, 2021, 43(9): 883-892. |
[6] | 丁彩红, 熊瑜, 王庆, 高绪胜, 郝焱. 含贝达喹啉方案治疗耐多药肺结核的早期疗效和安全性研究[J]. 中国防痨杂志, 2021, 43(9): 893-898. |
[7] | 吴国兰, 高静韬, 陈晓红, 陈力舟, 翁丽珍, 郭志平, 陈秀平, 林剑东, 陈素霞, 高孟秋, 刘宇红. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的近期疗效及安全性分析[J]. 中国防痨杂志, 2021, 43(9): 899-904. |
[8] | 石文卉, 初乃惠. 耐药肺结核患者氟喹诺酮类药物耐药情况及影响因素[J]. 中国防痨杂志, 2021, 43(9): 905-909. |
[9] | 张婷, 苏倩, 吴成果, 汪清雅, 雷蓉蓉, 陈健. 重庆市肺结核患者直接医疗费用及其影响因素分析[J]. 中国防痨杂志, 2021, 43(9): 910-915. |
[10] | 赵秀娟, 莫菁莲, 孙涛, 刘琳, 钟业腾, 裴华, 夏乾峰. 2015—2019年海南省省级结核病定点医疗机构收治的肺结核患者耐药特征及相关因素分析[J]. 中国防痨杂志, 2021, 43(9): 916-923. |
[11] | 林建, 林淑芳, 戴志松, 赵永, 周银发, 张添林, 魏淑贞. 2016—2019年福建省结核病耐药监测结果分析[J]. 中国防痨杂志, 2021, 43(9): 924-928. |
[12] | 李婷, 何金戈, 夏岚, 陈闯, 肖月, 逯嘉, 王丹霞. 新型冠状病毒肺炎疫情对四川省结核病患者登记情况的影响分析[J]. 中国防痨杂志, 2021, 43(9): 929-938. |
[13] | 易一行, 喻容, 石国民, 马小华, 肖四方, 税剑, 范任华, 向延根. 基于16S rRNA V4区高通量测序的初治菌阳肺结核患者肠道菌群构成与表型分析[J]. 中国防痨杂志, 2021, 43(9): 939-946. |
[14] | 周莹宇, 付雷, 张炜焱, 王彬, 陈曦, 陆宇, 陈效友. 不同耐药类型结核分枝杆菌毒力变化的初步研究[J]. 中国防痨杂志, 2021, 43(9): 952-960. |
[15] | 马婷婷, 任斐, 马进宝, 杨翰. 异烟肼耐药肺结核患者对丙硫异烟胺和对氨基水杨酸的耐药情况分析[J]. 中国防痨杂志, 2021, 43(9): 961-964. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||